Envisia Therapeutics

Acquired

Envisia Therapeutics is a biotech company in Research Triangle Park, United States, founded in 2013. It has raised $41.5M across 2 rounds, most recently a $16.5M Extension Round in March 2016.

Extended-release drug delivery for eye disease

Employees
11–50
Founded
2013
Business Model
B2B
Total Funding
$41.5M
Last Round
$16.5M Extension RoundMar 2016
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 5 investors for this company. The full record is or through the API.

About

Envisia Therapeutics is a clinical-stage biotechnology company based in Morrisville (Research Triangle Park), North Carolina, focused on developing novel sustained-release drug delivery platforms for ophthalmic diseases. The company's lead product, ENV515, is an extended-release travoprost implant for the treatment of open-angle glaucoma and ocular hypertension. Envisia employs engineered nanoparticle technology for both front-of-eye and back-of-eye drug delivery applications, and debuted with a $25 million Series A financing in November 2013.

Summary

It lists 11–50 employees. It has raised $41.5M in total across 2 rounds, most recently a $16.5M Extension Round in Mar 2016. Investors include Canaan Partners, New Enterprise Associates and Pappas Capital.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Extension RoundExtension RoundMar 2016
$16.5M

Sign up to see all 2 events

Funding: Series A through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Envisia Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/envisia-therapeutics"><img src="https://indexed.vc/api/badge/company/envisia-therapeutics" alt="Envisia Therapeutics on Indexed.vc" width="260" height="76" /></a>